Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 480,240 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 480,240 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $22.79, for a total transaction of $10,944,669.60. Following the completion of the sale, the director owned 875,912 shares in the company, valued at approximately $19,962,034.48. This trade represents a 35.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Performance

DYN opened at $23.83 on Thursday. The stock has a 50-day moving average of $19.00 and a 200 day moving average of $18.28. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $25.00. The firm has a market cap of $3.94 billion, a P/E ratio of -7.40 and a beta of 1.06.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the prior year, the business earned ($1.05) earnings per share. As a group, research analysts forecast that Dyne Therapeutics, Inc. will post -3.02 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on DYN shares. TD Cowen initiated coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating for the company. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Sanford C. Bernstein upped their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Finally, Evercore set a $33.00 price target on Dyne Therapeutics in a research note on Friday, May 15th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Hilton Head Capital Partners LLC bought a new stake in Dyne Therapeutics during the 1st quarter valued at $26,000. Strs Ohio bought a new position in shares of Dyne Therapeutics during the 4th quarter worth $51,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Dyne Therapeutics during the fourth quarter valued at $84,000. Steward Partners Investment Advisory LLC increased its stake in shares of Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after acquiring an additional 7,697 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.